FHA
CRNX icon

First Horizon Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

First Horizon Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$10.4K Hold
361
– – ﹤0.01% 1672
2025
Q1 		$12.1K Hold
361
– – ﹤0.01% 1529
2024
Q4 		$18.5K Hold
361
– – ﹤0.01% 1357
2024
Q3 		$18.4K Buy
361
+121
+50% +$6.24K ﹤0.01% 1390
2024
Q2 		$10.7K Hold
240
– – ﹤0.01% 1501
2024
Q1 		$11.2K Buy
+240
New +$9.39K ﹤0.01% 1539

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Horizon Advisors's CRNX Position: Q2 2025 in Review

First Horizon Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2025 at 361 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

First Horizon Advisors first reported a position in CRNX in Q1 2024 and has held it in 6 quarters since. The position peaked at $18.5K in Q4 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • First Horizon Advisors held 361 shares of Crinetics Pharmaceuticals worth $10.4K as of Q2 2025.
  • First Horizon Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2025.
  • Crinetics Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1672 holding.
  • First Horizon Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • First Horizon Advisors's Crinetics Pharmaceuticals position peaked at $18.5K in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.